The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
Temple
R
R
Office of Drug Evaluation, United States Food and Drug Administration, Rockville, Maryland, USA.
D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004341:Drug Evaluation / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D014481:United States; D014486:United States Food and Drug Administration
D015507:Drugs, Investigational; D000960:Hypolipidemic Agents; D008055:Lipids; D002784:Cholesterol